Prevnar 13 is a vaccine used to treat adults with pneumococcal disease, including pneumonia. Global revenues from the drug grew by 48%.
A lower effective tax rate and share repurchases had a positive impact on EPS. The company has consistently beaten Wall Street analysts’ EPS estimates for the last eight quarters.
Though Centene’s EBITDA margins remained at 2.8% in both 1Q14 and 1Q15, they declined sequentially from 4.6% in 4Q14.
By the end of 1Q15, Centene (CNC) offered health insurance services to about 184,000 dual eligible members.
In 1Q15, Centene served about 161,700 members across 11 states through the public exchanges, which was a rise of 307.3% from the 39,700 members the company served in 1Q14.
Centene’s premium and service revenues increased by 42% from $3.35 billion in 1Q14 to $4.76 billion in 1Q15.
Centene (CNC) posted its 1Q15 earnings on April 28, 2015. The company beat the Wall Street diluted EPS estimates of $0.49 with a posted EPS of $0.52.
Aetna’s EBITDA margins rose from 10.6% in 1Q14 to 11.3% in 1Q15. Enrollment growth and an effective cost optimization strategy led to the high margins.
Aetna’s (AET) revenues from commercial enrollments increased by 5.8% in 1Q15. Public exchange membership was the primary driver of this growth.
As part of its payment strategy, Aetna projects its value-based spending as part of its total spending to rise from 25% in 2014 to 75% in 2020.
Aetna’s revenues from government-sponsored enrollments increased 12.4% in 1Q15. Total government enrollments increased sequentially by 85,000 members.
Aetna (AET) announced its 1Q15 earnings on April 28, 2015. The company posted EPS of $2.30, beating Wall Street EPS estimates of $1.94.
On April 23, Novartis shares started trading at $105.50, up 2% from the previous day’s closing of $103.40. It driven by the significant increase in EPS.
Novartis’s (NVS) recent deals bode well for robust growth in its oncology business.
Novartis (NVS) reported adjusted operating margins of 30.6% in 1Q15, up by 0.8% from 1Q14. The currency had a negative impact of 0.9%.
Novartis (NVS) missed analysts’ revenue estimates in 1Q15 by 4.5%. Lower international revenue due to a strong US dollar led to a 10% decline in revenue.
Novartis (NVS) posted its 1Q15 earnings on April 23. Novartis beat Wall Street adjusted earnings per share estimates of $1.06, posting $1.29, a 21.7% growth.
Universal Health Services (UHS) earns more than 50% of its total revenue from the markets in Texas, Nevada, Florida, California, and Washington DC.
In 1Q15, Universal Health Services’ (UHS) operating charges—as a percentage of its net revenue—were 79.8%. This was an improvement of 0.2%.
Universal Health Services’ behavioral health segment registered 14% growth in total revenue—from $946 million in 1Q14 to $1,076.3 million in 1Q15.